Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed360%
terminated120%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)

NCT04963088
terminatedphase_1

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

NCT03379259
completedphase_1

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial

NCT03287427
completedphase_1

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

NCT02407990
unknownphase_2

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

NCT04815408

Clinical Trials (5)

Showing 5 of 5 trials
NCT04963088Phase 1

Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)

Completed
NCT03379259Phase 1

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Terminated
NCT03287427Phase 1

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial

Completed
NCT02407990Phase 1

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Completed
NCT04815408Phase 2

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5